Inspira Technologies Secures $580,000 NYU Langone Order for FDA-Cleared ART100
Inspira Technologies secured a $580,000 purchase order from NYU Langone Hospital for FDA-cleared ART100 extracorporeal blood circulation systems after a multi-patient evaluation treating over 30 patients in cardiopulmonary and surgical procedures. The systems, ordered through its U.S. distributor, will be fulfilled immediately and provide a reference for ongoing strategic processes.
1. Purchase Order Details
Inspira has received a $580,000 purchase order from NYU Langone Hospital for its FDA-cleared ART100 extracorporeal blood circulation systems, placed through its U.S. distributor. The order is scheduled for immediate fulfillment and marks the company’s first commercial sale to a top-tier academic medical center.
2. Clinical Evaluation Outcomes
NYU Langone conducted a hospital-based evaluation in which ART100 systems treated more than 30 patients across cardiopulmonary bypass and surgical cases. The trial provided staff with operational experience integrating the device into workflows, directly leading to the transition from clinical assessment to procurement.
3. Strategic Process Implications
The NYU Langone purchase serves as a key commercial reference point in Inspira’s ongoing strategic discussions involving the ART100 platform and additional medical assets. Company executives view this milestone as strengthening negotiating positions with multiple counterparties for potential transactions.
4. FDA Clearance and Market Expansion
The ART100 system is FDA-cleared for cardiopulmonary bypass procedures and is under evaluation at other U.S. hospitals. Inspira is leveraging this clearance and the NYU Langone reference to pursue broader U.S. and international market entry.